PLoS ONE (Jan 2018)

Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis.

  • Mahn-Won Park,
  • Gyung-Min Park,
  • Seungbong Han,
  • Yujin Yang,
  • Yong-Giun Kim,
  • Jae-Hyung Roh,
  • Hyun Woo Park,
  • Jon Suh,
  • Young-Rak Cho,
  • Ki-Bum Won,
  • Soe Hee Ann,
  • Shin-Jae Kim,
  • Dae-Won Kim,
  • Sung Ho Her,
  • Sang-Gon Lee

DOI
https://doi.org/10.1371/journal.pone.0207889
Journal volume & issue
Vol. 13, no. 12
p. e0207889

Abstract

Read online

ObjectivesIt is unclear whether high-intensity statin therapy provides incremental clinical benefits over moderate-intensity statin therapy in Asian patients with angina. This study sought to compare the clinical outcomes of moderate- and high-intensity statin therapies in patients undergoing percutaneous coronary intervention (PCI) for angina in Korean patients.MethodsBased on the national health insurance claims data in South Korea, patients aged 18 years or older without a known history of coronary artery disease, who underwent PCI with drug-eluting stents due to angina between 2011 and 2015, were enrolled. According to the intensity of statin therapy, patients were categorized into moderate-intensity statin therapy (n = 23,863) and high-intensity statin therapy (n = 9,073) groups. The primary endpoint, defined as a composite of all-cause death and myocardial infarction, was compared between the two groups using a propensity-score matching analysis.ResultsDuring the follow-up period (median, 2.0 years; interquartile range, 1.1-3.1), 1,572 patients had 1,367 deaths and 242 myocardial infarctions. After propensity-score matching, there were 8,939 matched pairs. There was no significant difference in the incidence of the primary endpoint between the two groups (adjusted hazard ratio of high-intensity statin therapy, 1.093; 95% confidence interval: 0.950-1.259; p = 0.212).ConclusionsIn Korean patients undergoing PCI with drug-eluting stents for angina, the high-intensity statin therapy did not provide additional clinical benefits over the moderate-intensity statin therapy.